Is BillionToOne, Inc. (BLLN) Halal?

NASDAQ Healthcare United States $3.2B
? INSUFFICIENT DATA
Confidence: 8/100
BillionToOne, Inc. (BLLN) has insufficient data for a complete Shariah compliance screening. This may be due to missing financial statements or incomplete market data.

Shariah Screening — 5 Standards

Based on financial data from December 2025

Standard Debt Ratio Cash Ratio Receivables Income Status
AAOIFI N/A N/A N/A N/A ? INSUFFICIENT DATA
DJIM N/A N/A N/A N/A ? INSUFFICIENT DATA
MSCI N/A N/A N/A N/A ? INSUFFICIENT DATA
S&P N/A N/A N/A N/A ? INSUFFICIENT DATA
FTSE N/A N/A N/A N/A ? INSUFFICIENT DATA

Financial Highlights

P/E Ratio
496.8
Forward: 77.7
EPS
$0.14
P/B Ratio
6.6
EV/EBITDA
122.5
EV: $2.8B
Revenue
$305M
Growth: 113.1%
Current Ratio
11.7

Profitability

Gross Margin 68.3%
Operating Margin 10.8%
Net Margin 1.0%
Return on Equity (ROE) 2.3%
Return on Assets (ROA) 2.1%

Cash Flow & Balance Sheet

Operating Cash Flow$25M
Free Cash Flow$16M
Total Debt$109M
Debt-to-Equity22.7
Current Ratio11.7
Total Assets$633M

Price & Trading

Last Close$71.44
50-Day MA$80.23
200-Day MA$89.66
Avg Volume267K
52-Week Range
$61.96
$138.70

About BillionToOne, Inc. (BLLN)

CEO
Dr. Oguzhan Atay Ph.D.
Employees
713
Sector
Healthcare
Industry
Diagnostics & Research
Country
United States
Exchange
NASDAQ
Market Cap
$3.2B
Currency
USD

BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California.

Related Halal Stocks in Healthcare

Frequently Asked Questions

Is BillionToOne, Inc. (BLLN) halal to invest in?

Based on our screening using AAOIFI Standard 21 (the strictest methodology), BillionToOne, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.

What is BillionToOne, Inc.'s debt ratio?

BillionToOne, Inc.'s debt ratio is not available under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%.

What are BillionToOne, Inc.'s key financial metrics?

BillionToOne, Inc. has a market capitalization of $3.2B, trailing P/E ratio of 496.8, and revenue of $305M. The company maintains a gross margin of 68.3% and a net margin of 1.0%. Return on equity stands at 2.3%.

How often is the screening data updated?

Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.

Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.